Johnson & Johnson (JNJ) Key Developments | Reuters.com
Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

115.63USD
24 Jun 2016
Change (% chg)

$-1.75 (-1.49%)
Prev Close
$117.38
Open
$115.07
Day's High
$117.12
Day's Low
$115.00
Volume
13,939,481
Avg. Vol
7,448,979
52-wk High
$117.74
52-wk Low
$81.79

Latest Key Developments (Source: Significant Developments)

Gilead says European Commission grants marketing authorization for Odefsey®
Thursday, 23 Jun 2016 07:53am EDT 

Gilead Sciences Inc : European Commission grants marketing authorization for Gilead's single tablet regimen Odefsey® (emtricitabine, rilpivirine, tenofovir alafenamide) for the treatment of HIV . Gilead sciences says under agreement, co is responsible for manufacturing, registration, distribution, commercialization of Odefsey in most countries . Odefsey approval is part of ongoing development and commercialization agreement between Gilead And Janssen, first established in 2009 .Says Janssen will distribute it in approximately 18 markets and have co-detailing rights in several key markets.  Full Article

UK's CMA says Reckitt Benckiser licensed K-Y brand to Thornton & Ross
Monday, 20 Jun 2016 09:10am EDT 

Competition and Markets Authority : Reckitt Benckiser licensed K-Y brand to Thornton & Ross for 8 years and completed its merger with Johnson & Johnson Link to source: (http://bit.ly/28ITo7z) (((Bengaluru Newsroom +91 806 749 1136);)).  Full Article

Janssen announces data from Phase 3 MMY3003 (POLLUX) trial
Friday, 10 Jun 2016 07:00am EDT 

Janssen: Janssen Research & Development Llc announced today data from Phase 3 MMY3003 (POLLUX) trial . In addition to meeting primary endpoint of improved PFS daratumumab doubled rate of complete responses (CR) or better . Daratumumab significantly extended progression-free survival in combination with lenalidomide and dexamethasone in patients with multiple myeloma .Says additionally daratumumab significantly increased overall response rate.  Full Article

Amyris announces collaboration with Johnson & Johnson Innovation
Monday, 6 Jun 2016 08:30am EDT 

Amyris Inc : Amyris announces collaboration with Johnson & Johnson innovation for biosynthetic drug discovery .Collaboration will use μpharm to develop customized library of natural, natural-like compounds to test against Janssen's therapeutic target.  Full Article

Johnson & Johnson to acquire Vogue International for about $3.3 bln
Thursday, 2 Jun 2016 06:45am EDT 

Johnson & Johnson : Johnson & Johnson announces agreement to acquire Vogue International . Johnson & Johnson says deal valued at about $3.3 billion in cash . Acquisition strengthens co's position in hair care and other personal care products . Transaction is not expected to impact 2016 sales or earnings guidance ranges that Johnson & Johnson announced on April 19, 2016 .Johnson & Johnson says transaction is expected to close during Q3 of 2016.  Full Article

Janssen Pharmaceutica NV says Idylla ebola virus test granted emergency use authorization by U.S. FDA
Wednesday, 1 Jun 2016 01:00am EDT 

Janssen Pharmaceutica Nv: Idylla ebola virus triage test was granted emergency use authorization (eua) by u.s. Food and drug administration .Idylla ebola virus triage test detects presence of ebola zaire virus in patients with signs and symptoms of ebola virus disease.  Full Article

European Commission approves Johnson & Johnson's TREVICTA
Tuesday, 31 May 2016 07:00am EDT 

Johnson & Johnson :Janssen-Cilag International NV says European Commission (EC) has approved use of TREVICTA for maintenance treatment of schizophrenia in adult patients.  Full Article

Johnson & Johnson says collaborating with HP Inc's unit
Tuesday, 17 May 2016 08:52am EDT 

Johnson & Johnson : Johnson & Johnson announces collaboration with HP Inc. subsidiary to create personalized health care solutions with 3D printing technologies . "collaboration is focused on using 3D printing technologies to create better health care outcomes at reduced costs" . "collaboration announced today has already begun, with teams of experts from both organizations working together" .In near-term, collaboration will focus on personalization of instrumentation and software for patient-specific healthcare devices.  Full Article

Manitex Capital declares a dividend-in-kind
Tuesday, 10 May 2016 04:51pm EDT 

Manitex Capital Inc : Declared a special dividend-in-kind of 1.3 million class "a" common shares of Ortho Regenerative Technologies held by Manitex . Dividend has a deemed price of $0.50 per ortho share and is payable on, or about, June 3, 2016 .Declares a dividend-in-kind of shares of Ortho Regenerative Technologies Inc..  Full Article

Johnson & Johnson says Janssen unit received civil investigative demand from U.S. Attorney’s office for Southern district of New York
Tuesday, 10 May 2016 06:40am EDT 

Johnson & Johnson : In march, janssen pharmaceuticals received a civil investigative demand from the u.s. attorney’s office for the southern district of new york . Demand related to janssen's contractual relationships with pbms over period from jan 1, 2006 to present related to certain of jpi's pharma products .Demand was issued in connection with an investigation under the false claims act.  Full Article

J&J asks 5th Circuit to delay next Pinnacle hip bellwether trial

Johnson & Johnson and its DePuy Orthopaedics unit have asked a federal appeals court to halt an upcoming bellwether trial over their Pinnacle metal-on-metal hip implants until their challenges to a previous $502 million verdict are resolved.